Exelixis Inc. (EXEL)
NASDAQ: EXEL
· Real-Time Price · USD
41.74
0.15 (0.36%)
At close: Jun 16, 2025, 3:59 PM
41.60
-0.34%
After-hours: Jun 16, 2025, 07:55 PM EDT
0.36% (1D)
| Bid | 41.55 |
| Market Cap | 11.38B |
| Revenue (ttm) | 2.3B |
| Net Income (ttm) | 643.57M |
| EPS (ttm) | 2.19 |
| PE Ratio (ttm) | 19.06 |
| Forward PE | 15.82 |
| Analyst | Buy |
| Ask | 41.6 |
| Volume | 1,320,331 |
| Avg. Volume (20D) | 2,970,490 |
| Open | 41.65 |
| Previous Close | 41.59 |
| Day's Range | 41.53 - 42.07 |
| 52-Week Range | 21.36 - 48.85 |
| Beta | 0.28 |
About EXEL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EXEL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EXEL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+3.61%
Exelixis shares are trading higher after the compa...
Unlock content with
Pro Subscription
1 month ago
+20.84%
Exelixis shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates. The company, acting as a collaboration partner of Invenra, initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628.
